サイトの移動について

ルンドベック・ジャパン(www.lundbeck.co.jp)以外のサイトへ移動します。よろしければ、下記リンク先をクリックしてください。

移動する

キャンセル

パイプライン

開発中の治療法

私たちの研究開発部門は、精神・神経疾患メカニズムの解明を目指しています。標準治療を見直し、精神・神経疾患領域で薬の開発が必要とする領域において、最もニーズが高い分野に対応する新たな治療法を患者さんに届けるという、ただ一つの目標に向かって歩んでいます

Hormonal / neuropeptide signaling

Project Area Phase 1 Phase 2 Phase 3 Filing
Eptinezumab (anti-CGRP mAb)¹ ¹⁰ Migraine prevention² Filing

Mode of Action

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Lu AG09222 (anti-PACAP mAb)³ Migraine prevention² 2

Mode of Action

Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.

Lu AG13909 (anti-ACTH mAb)⁴ Neurohormonal dysfunctions 1

Circuitry / neuronal biology

Project Area Phase 1 Phase 2 Phase 3 Filing
Brexpiprazole⁵ PTSD⁶ Filing

Mode of Action

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AF28996 (D1-D2 agonist)⁷ Parkinson's disease 1

Mode of Action

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

MAGLi program⁸ Neurology 1
Bexicaserin (5HT2C agonist) Developmental and epileptic encephalopathies 3

Protein aggregation, folding and clearance

Project Area Phase 1 Phase 2 Phase 3
Amlenetug (anti α-synuclein mAb) Synucleinopathies (MSA) 3

Neuroinflammation / Neuroimmunology

Project Area Phase 1 Phase 2 Phase 3
Lu AG22515 (CD40L blocker)⁹ Neurology 1

 

上記開発ステージは、ルンドベックグローバルの開発ステージとなります。

ルンドベックについてさらに知る